← boardnext 2026-09
APGE
Apogee Therapeutics, Inc.distress 2/10 · well-funded / low risk$134.11+0%today0% from 52w high
Respiratory 1
Lead: atopic dermatitis · target IL-13 · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$1258M
Runway
5.4 yrs
Shares 1y
—
Price & events
+67.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.9%
1M
+51.9%
3M
+91.5%
6M
+230.5%
1Y
+165.6%
2Y
—
5Y
+531.7%
All
Overview
- Volume
- 76.56K
- 52 Week Range
- $34.65 – $134
- Float Shares
- 59.27M
- Short %
- 10.84%
- % Held by Insiders
- 2.37%
- % Held by Institutions
- 110.00%
- RVOL
- 0.02x
- Beta
- 0.33
Pipeline stages · 1 programs
APG777
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-01 final ~2027-03-01 | Phase 1 | APG777 | Asthma | 31 | active not recruiting |
| 2026-11 Estimated 50% readout ~2026-12-16 | Phase 2 | APG777 | Atopic Dermatitis | — | active not recruiting |
| 2029-12 Estimated 50% readout ~2030-01-15 | Phase 2 | APG777 | Atopic Dermatitis | — | recruiting |
Catalyst news & presentations · 30
- second half of 2028Guided 55%readoutPhase 3zumilokibart · Phase 3 ADventure TCS data readoutSEC 8-K
- first half of 2028Guided 55%readoutPhase 3zumilokibart · Phase 3 ADventure 1 and 2 data readoutSEC 8-K
- second half of 2027Guided 55%readoutPhase 2zumilokibart · Phase 2 APEX Part A 2-year follow-up dataSEC 8-K
- first half of 2027Guided 55%readoutPhase 2zumilokibart · Phase 2 APEX Part B 52-week maintenance dataSEC 8-K
- first half of 2027Guided 55%trial initiationsecondaryPhase 2zumilokibart · Initiation of Phase 2b ASPIRE trialSEC 8-K
- 2026Guided 40%trial initiationsecondaryPhase 3APG777 · Initiation of Phase 3 trial.SEC 8-K
- 2026Guided 40%readoutPhase 2APG777 · Phase 2b asthma data expectedSEC 8-K
- 2H 2026Guided 55%trial initiationsecondaryPhase 3zumilokibart (APG777) · Initiation of Phase 3 trial in AD.SEC 8-K
- second half of 2026Guided 55%readoutPhase 1APG279 · Phase 1b head-to-head vs DUPIXENT interim readoutSEC 8-K
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
- 1H 2026readoutPhase 1APG777 · Phase 1b readout in mild-to-moderate asthmaSEC 8-K
- second half of 2026trial initiationsecondaryPhase 3APG777 · Phase 3 trial initiationSEC 8-K
- Q2 2026readoutPhase 2zumilokibart (APG777) · APEX Part B 16-week induction data readout.SEC 8-K
- second half of 2026readoutPhase 1/2APG279 · Phase 1b head-to-head interim readoutSEC 8-K
- 2026-06-18partnershipEntry into Agreement and Plan of Merger with AbbVie for acquisition at $135.11 per shareSEC 8-K
- 2026-05-26partnershipzumilokibart · Entered revenue participation agreement with Blackstone Life Sciences for up to $1.3B in funding.SEC 8-K
- Q1 2026readoutPhase 2APG777 · APEX 52-week Part A maintenance dataSEC 8-K
- Q1 2026readoutPhase 2zumilokibart (APG777) · APEX Part A 52-week maintenance data readout.SEC 8-K
- 2025trial initiationsecondaryAPG777, APG990 · First combination trial of APG777 and APG990SEC 8-K
- 2025trial initiationsecondaryPhase 1APG333 · Phase 1 trial initiation in HVsSEC 8-K
- 2025readoutPhase 1APG990 · Interim safety and PK data expectedSEC 8-K
- second half of 2025readoutPhase 2APG777 · 16-week topline data from Part A of Phase 2 trialSEC 8-K
- second half of 2025readoutPhase 1APG333 · Phase 1 dataSEC 8-K
- 2025trial initiationsecondaryPhase 1APG279 · Initiate Phase 1b head-to-head trial vs DUPIXENTSEC 8-K
- by the end of the yearenrollment completesecondaryPhase 2APG777 · APEX Phase 2 Part B enrollmentSEC 8-K
- mid-2025readoutPhase 2APG777 · 16-week topline data from Part A of Phase 2 trialSEC 8-K
- first half of 2025readoutPhase 1APG990 · Phase 1 healthy volunteer resultsSEC 8-K
- first half of 2025trial initiationsecondaryPhase 1APG777 · initiate Phase 1b trial in asthmaSEC 8-K
- first half of 2025readoutPhase 1APG808 · Data from Phase 1b asthma trialSEC 8-K
- second half of 2025readoutPhase 2APG777 · 16-week proof-of-concept data from Phase 2 Part A trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $131 (-3% upside) · 12 analysts
- 2026-06-24TD CowenBuy → Hold
- 2026-06-24GuggenheimBuy → Neutral
- 2026-06-24MizuhoOutperform → Neutral
- 2026-06-24StifelBuy → Hold
- 2026-06-23WedbushOutperform → Neutral
- 2026-06-23RBC CapitalSector Perform
Competitors — IL-13
- none identified
Recent news
- 2026-07-21Apogee Therapeutics stock hits all-time high at 134.34 USD - Investing.com
- 2026-07-18APGE Stock Alert: Halper Sadeh LLC is Investigating Whether Apoge - The National Law Review
- 2026-07-17Apogee Therapeutics (APGE) Proxy filing Summary - Quartr
- 2026-07-17Form 4 Apogee Therapeutics Inc For: 16 July By Investing.com - Investing.com South Africa
- 2026-07-17Form 4 Apogee Therapeutics Inc For: 16 July By Investing.com - Investing.com Nigeria
- 2026-07-17Apogee Therapeutics (APGE) CMO donates 8,000 shares to donor advised fund - Stock Titan
- 2026-07-15FMR LLC Significantly Reduces Stake in Apogee Therapeutics Inc. - GuruFocus
- 2026-07-14Halper Sadeh LLC is Investigating Whether NEE, CRBG, RMAX, APGE are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.